Form 8-K NEKTAR THERAPEUTICS For: Apr 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Nektar Therapeutics (NKTR) Regains Nasdaq Compliance
April 17, 2024 5:07 PM EDTAs previously disclosed, on May 26, 2023, Nektar Therapeutics (NASDAQ: NKTR) received a notice from the Nasdaq Listing Qualifications Department (the Staff) stating that the Company was not in compliance with the minimum bid price requirement of $1.00 per share (the Minimum Bid Price Requirement) for continued listing on the Nasdaq Global Market because... More
